Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses HORIZON (NCT02963493), an exploratory analysis of time to next treatment in patients with relapsed/refractory (R/R) multiple myeloma who received melflufen plus dexamethasone. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).